Analysis of medication data of women with uterine fibroids based on data mining technology
article
OA: gold
CC0
⤵ 2 in-corpus citations
AI-generated summary
Data mining of Chinese literature from 2004-2018 identified mifepristone as a frequently used, effective, and well-tolerated medication for treating uterine fibroids.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The purpose of this study was to analyze the characteristics of the diagnosis and treatment of female uterine fibroids based on data mining technology and the medication rule. Clinical literature related to the treatment of uterine fibroids by Chinese National Knowledge Infrastructure (CNKI) from 2004 to 2018 were searched, and the literature meeting the requirements were selected according to the inclusion criteria and exclusion criteria. The contents of the prescription were recorded into the database, and the results of drug frequency, common drugs and core rules, etc. were obtained by the rule analysis of the software, so as to analyze the medication rules of modern doctors in treating uterine fibroids. Through research and analysis, it showed that common clinical drugs include leuprorelin (GnRH-a), danazol (androgen), gestrinone (progestin), mifepristone (progesterone receptor antagonist), and some cases of combination therapy. Based on the analysis of the frequency of drug, treatment effect and adverse drug reactions, it was found that the clinical application of mifepristone in the treatment of uterine fibroids was relatively common, with significant drug effect and mild adverse reactions, which was worthy of clinical promotion and application. Therefore, the results of this study provide a new basis for the clinical and basic research of traditional Chinese medicine in the treatment of uterine fibroids, but it still needs the verification of expert interpretation, experimental research and other methods.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
Cited by (2)
References (21)
- Drug delivery for the treatment of endometriosis and uterine fibroids via openalex
- doi:10.1055/s-0038-1636516 via openalex
- doi:10.12659/msm.909143 via openalex
- doi:10.1186/s10397-017-1014-4 via openalex
- doi:10.1016/j.cellsig.2018.01.025 via openalex
- doi:10.18632/oncotarget.16520 via openalex
- doi:10.1007/s13346-016-0323-x via openalex
- doi:10.3390/ijms19072051 via openalex
- doi:10.1080/17460441.2018.1417381 via openalex
- doi:10.1016/j.ejogrb.2016.11.003 via openalex
- doi:10.1016/j.gore.2017.10.003 via openalex
- doi:10.3892/ol.2018.8325 via openalex
- doi:10.1080/17460441.2018.1394839 via openalex
- W6742793713 via openalex
- W6746474884 via openalex
- W6750002508 via openalex
- W6769335793 via openalex
- doi:10.6515/acs.201801_34(1).20170901b via openalex
- doi:10.1016/j.ejogrb.2018.07.032 via openalex
- doi:10.1016/j.ejogrb.2018.03.026 via openalex
- doi:10.4103/0973-1482.235342 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-11T05:42:58.953575+00:00
License: CC0
· commercial use OK